Navigation Links
InteKrin Therapeutics' Co-Founder Receives Appointment as Professor of Medicine at Harvard Medical School
Date:2/8/2010

LOS ALTOS, Calif., Feb. 8 /PRNewswire/ -- InteKrin Therapeutics Inc announced today that the Company's co-founder and Scientific Advisory Board Chairman, Christos Mantzoros, M.D., DSc., FACP, FACE, has been appointed Professor of Medicine at Harvard Medical School and Professor in Environmental Health at the Harvard School of Public Health.

Dr. Mantzoros is a member of Harvard's Division of Endocrinology, Diabetes, and Metabolism, and is an acknowledged expert in the fields of insulin resistance, body weight regulation, adipokine biology, and energy homeostasis. He has published more than 200 original papers and more than 100 reviews and chapters which have received more than 12,000 citations. He has received several national and international awards and has also been elected a member of The American Society for Clinical Investigation (ASCI).

Dr. Mantzoros, who trained at Harvard, serves as Founding Director of the Human Nutrition Research Unit and as the Clinical Research Overseer at Beth Israel Deaconess Medical Center and the Joslin Diabetes Center. In conjunction with his new appointment, he will also be assuming responsibilities as Chief of Endocrinology and Diabetes at the Greater Boston VA Healthcare System, a system of three hospitals and six outpatient clinics in the greater Boston area which are affiliated with Harvard Medical School.

Dennis M. Lanfear, President and Chief Executive Officer, and Dr. Mantzoros founded InteKrin Therapeutics Inc in 2005. Dr. Mantzoros remains an integral part of InteKrin Therapeutics' management team and regularly advises on scientific matters.

About InteKrin (www.InteKrin.com):

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin's team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clinical and commercialization leaders.

SOURCE InteKrin Therapeutics Inc


'/>"/>
SOURCE InteKrin Therapeutics Inc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study of Diabetes Meeting
2. InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting
3. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
4. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
5. BioMarin to Acquire LEAD Therapeutics
6. Medical Research Council Technologys Centre for Therapeutics Discovery Opens its First Call For Targets in an Effort to Develop Drugs in Areas of Serious Unmet Need
7. Vantia Therapeutics Lead Candidate VA106483 Enters Phase IIb Trial for Nocturia
8. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
9. Pepscan Therapeutics Strengthens Management Team
10. PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy
11. NASDAQ Trading for Oxygen Biotherapeutics, Inc. Shares to Begin January 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Israel , March 27, 2017 ... oncology and immunology, announced today that AGI-134, an immunotherapy for ... acquisition of Agalimmune Ltd., will be featured at the upcoming ... in Washington, DC to be held ... ...
(Date:3/27/2017)... The staggering cost of cancer treatment means ... to the latest treatment options against cancer. Even among ... have inadequate or no health insurance and are oftentimes ... to modern cancer treatment is almost non-existent for cancer ... The mission statements of pharmaceutical and biotech companies often ...
(Date:3/27/2017)... , March 27, 2017 ... as the NASDAQ Composite closed the trading session up ... and the S&P 500 was down 0.08%. US markets ... sectors finishing the day in green. Pre-market today, Stock-Callers.com ... Medical Group N.V. (NASDAQ: WMGI), Amedica Corporation (NASDAQ: AMDA), ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... Adding to ... England Journal of Medicine and NEJM Journal Watch, announces the release of ... created by a panel of pediatricians from leading medical centers. The content was ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... The comprehensive weight management program at Women’s Excellence will help patients lose weight ... and physical exam. The specialists at Women's Excellence will measure BMI, body ...
(Date:3/27/2017)... ... ... Janet Schloz is still in shock after receiving a $2,500 Academic Award from California ... she said. , She thinks the coming week is going to be a very joyful ... to help my students.” , The award will allow the 4th grade teacher at Tumwater ...
(Date:3/27/2017)... ... 2017 , ... ?Grow Healthy Vending LLC announced today that ... itself and 1800 Vending DBA Healthy You Vending. (Civil No. 1:14-CV-00121-CW/ United States ... that we have now reached a settlement agreement regarding the ongoing lawsuits between ...
(Date:3/26/2017)... ... March 26, 2017 , ... Local physician ... 100 Award, a prestigious award honoring the top influencers on RealSelf—the most trusted ... connect with doctors and clinics. , In 2016, more than 82 million people ...
Breaking Medicine News(10 mins):